BCMA CAR-T ciltacabtagene autoleucel approved in China for multiple myeloma
China's first BCMA-directed CAR-T takes cell therapy beyond CD19 lymphoma into plasma-cell disease — with a label restricted to patients who have already failed three lines.
At a glance
- Generic name
- Ciltacabtagene autoleucel
- Brand
- 卡卫荻 / Carvykti
- Development code
- LCAR-B38M / JNJ-68284528
- Regulatory status
- Conditionally approved in China (NMPA, 2024-08)
What happened
Legend Biotech announced NMPA approval of ciltacabtagene autoleucel on 27 August 2024; the NMPA published its approval notice on 12 September 2024. The approval is conditional, and covers adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
The product uses two tandem nanobody domains against BCMA rather than a conventional single-chain variable fragment. The Chinese approval rests on the CARTIFAN-1 study: in 58 evaluable patients, overall response rate was 87.9%, with 79.3% achieving complete or stringent complete response.
Why it matters
Targeting BCMA rather than CD19 opens cell therapy to multiple myeloma, a disease where patients typically cycle through several lines of treatment and run out of options.
It also broadens the infrastructure question. A myeloma CAR-T programme needs apheresis, a manufacturing link, and the capacity to manage cytokine release syndrome and prolonged cytopenias — a different clinical load from lymphoma CAR-T, where patients are often younger and fitter.
Access in China
Where it is available
Delivered at hospitals with a cellular-therapy programme; not every haematology department has one. Which centres currently run an active myeloma CAR-T programme, and which accept international self-pay patients, is not published — we confirm it during intake.
Language support
International departments at major public hospitals provide English support; haematology wards themselves generally do not.
Typical timeline
Leukapheresis, manufacture and release, lymphodepletion, infusion, then a monitored inpatient stay. Vein-to-vein time depends on manufacturing slot availability and is not published.
Cost
No figure is published here. We do not publish a price we cannot back with a written quotation from a specific hospital — ask us and we will obtain it in writing before you commit to anything.
What we don't know
These are the questions patients actually ask, and the ones nobody publishes. We list them rather than filling them with guesses.
- •No published list price for the product in China.
- •Manufacturing slot availability, and therefore the interval from apheresis to infusion.
- •Whether centres will accept a patient who has already received a CD19 CAR-T.
- •Bridging therapy policy differs by centre and is not published.
- •Supportive care and prolonged cytopenia management costs are billed separately and are not published.
Sources
- NMPA — approval of ciltacabtagene autoleucel injection
Original language: Chinese · Published 2024-09-12
- Legend Biotech — China approval announcement
Original language: Chinese · Published 2024-08-27
Need to know if this applies to you?
Send the diagnosis and treatment history. We check availability with the hospital, get the current price in writing, and tell you what has to happen before you travel.
Published 2024-08-27 . This page is general information, not medical advice, diagnosis or a recommendation for any individual. Regulatory status, availability and price can change without notice — confirm with the treating hospital before making decisions.